Geode Capital Management LLC Buys 137,087 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Geode Capital Management LLC raised its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 9.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,585,127 shares of the company's stock after purchasing an additional 137,087 shares during the period. Geode Capital Management LLC owned approximately 2.09% of Nurix Therapeutics worth $29,870,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of NRIX. Lord Abbett & CO. LLC bought a new stake in shares of Nurix Therapeutics in the 3rd quarter worth $7,879,000. Vanguard Group Inc. increased its stake in Nurix Therapeutics by 8.3% in the 4th quarter. Vanguard Group Inc. now owns 4,345,266 shares of the company's stock valued at $81,865,000 after buying an additional 333,452 shares during the last quarter. Norges Bank bought a new position in shares of Nurix Therapeutics during the 4th quarter worth approximately $6,006,000. Nikko Asset Management Americas Inc. boosted its stake in shares of Nurix Therapeutics by 42.8% in the 4th quarter. Nikko Asset Management Americas Inc. now owns 789,222 shares of the company's stock worth $14,869,000 after buying an additional 236,620 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in shares of Nurix Therapeutics by 42.7% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 789,222 shares of the company's stock valued at $14,869,000 after acquiring an additional 235,971 shares in the last quarter.

Nurix Therapeutics Stock Up 8.6 %

NASDAQ:NRIX traded up $0.91 during trading hours on Tuesday, hitting $11.46. 1,149,446 shares of the company's stock traded hands, compared to its average volume of 888,612. Nurix Therapeutics, Inc. has a 52 week low of $8.18 and a 52 week high of $29.56. The business's fifty day simple moving average is $12.93 and its two-hundred day simple moving average is $18.60. The firm has a market cap of $873.66 million, a P/E ratio of -3.97 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its quarterly earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.05. The firm had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter last year, the company posted ($0.76) EPS. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Insider Transactions at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 2,811 shares of the company's stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $55,798.35. Following the completion of the transaction, the chief financial officer now directly owns 39,549 shares in the company, valued at approximately $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Gwenn Hansen sold 3,690 shares of the firm's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $19.85, for a total value of $73,246.50. Following the sale, the insider now owns 55,937 shares in the company, valued at $1,110,349.45. The trade was a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,326 shares of company stock valued at $213,449 in the last quarter. Insiders own 7.40% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on NRIX. JPMorgan Chase & Co. reduced their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Morgan Stanley boosted their target price on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research note on Monday, February 3rd. Wells Fargo & Company decreased their price target on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Leerink Partners began coverage on Nurix Therapeutics in a research note on Monday, March 17th. They issued a "market perform" rating and a $16.00 price objective on the stock. Finally, Needham & Company LLC lowered their target price on Nurix Therapeutics from $28.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, April 9th. Three research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to MarketBeat, Nurix Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $30.44.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.